Neurocrine Biosciences, Inc.
Index- P/E881.85 EPS (ttm)0.12 Insider Own0.30% Shs Outstand95.60M Perf Week-1.73%
Market Cap9.97B Forward P/E28.90 EPS next Y3.63 Insider Trans-20.12% Shs Float93.96M Perf Month8.85%
Income12.20M PEG- EPS next Q0.79 Inst Own99.90% Short Float2.75% Perf Quarter22.31%
Sales1.30B P/S7.68 EPS this Y-78.00% Inst Trans0.51% Short Ratio3.45 Perf Half Y21.33%
Book/sh14.89 P/B7.05 EPS next Y109.28% ROA0.60% Target Price113.52 Perf Year14.30%
Cash/sh6.83 P/C15.37 EPS next 5Y-2.70% ROE0.90% 52W Range71.88 - 109.26 Perf YTD23.21%
Dividend- P/FCF75.15 EPS past 5Y20.70% ROI5.30% 52W High-3.24% Beta0.59
Dividend %- Quick Ratio3.50 Sales past 5Y137.50% Gross Margin98.60% 52W Low47.09% ATR3.22
Employees900 Current Ratio3.60 Sales Q/Q30.90% Oper. Margin-0.30% RSI (14)62.89 Volatility2.53% 3.39%
OptionableYes Debt/Eq0.00 EPS Q/Q-140.80% Profit Margin0.90% Rel Volume0.51 Prev Close104.94
ShortableYes LT Debt/Eq0.12 EarningsAug 04 AMC Payout0.00% Avg Volume749.19K Price105.72
Recom2.10 SMA206.09% SMA508.77% SMA20017.84% Volume169,523 Change0.74%
Jun-06-22Resumed Jefferies Buy $126 → $112
Mar-03-22Downgrade Piper Sandler Overweight → Neutral $114 → $94
Feb-25-22Upgrade Goldman Neutral → Buy $115
Jan-18-22Downgrade RBC Capital Mkts Outperform → Sector Perform $122 → $90
Nov-19-21Initiated BMO Capital Markets Underperform $76
Nov-17-21Upgrade JP Morgan Neutral → Overweight $124
Oct-14-21Downgrade Morgan Stanley Overweight → Equal-Weight $110 → $112
Sep-23-21Resumed Needham Hold
Aug-06-21Downgrade Canaccord Genuity Buy → Hold
May-18-21Resumed Goldman Neutral $108
May-06-21Upgrade Barclays Equal Weight → Overweight $110
Feb-02-21Initiated Raymond James Outperform $163
Sep-30-20Initiated The Benchmark Company Hold
Aug-04-20Downgrade JP Morgan Overweight → Neutral $136
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Aug-05-22 05:19PM  
Aug-04-22 07:05PM  
Jul-29-22 08:01AM  
Jul-28-22 10:02AM  
Jul-27-22 09:40AM  
Jul-23-22 08:02AM  
Jul-22-22 08:11AM  
Jul-21-22 04:05PM  
Jul-14-22 04:01PM  
Jul-11-22 02:20PM  
Jul-03-22 08:42AM  
Jun-21-22 04:17PM  
Jun-13-22 08:00AM  
Jun-08-22 04:01PM  
Jun-06-22 09:30AM  
May-24-22 09:40PM  
May-23-22 08:30AM  
May-12-22 07:37PM  
May-09-22 09:23AM  
May-05-22 04:30AM  
May-04-22 08:45AM  
May-03-22 04:01PM  
May-02-22 08:30AM  
Apr-27-22 03:03PM  
Apr-20-22 08:50AM  
Apr-13-22 04:01PM  
Apr-01-22 08:30AM  
Mar-28-22 04:01PM  
Mar-25-22 12:12PM  
Mar-24-22 08:30AM  
Mar-21-22 04:01PM  
Mar-01-22 04:01PM  
Feb-28-22 08:20AM  
Feb-11-22 08:45AM  
Feb-07-22 01:57PM  
Feb-04-22 03:00PM  
Feb-02-22 09:38AM  
Jan-25-22 04:01PM  
Jan-24-22 09:00AM  
Jan-12-22 05:38PM  
Jan-06-22 04:01PM  
Jan-03-22 04:01PM  
Dec-28-21 07:38AM  
Dec-17-21 10:38PM  
Dec-14-21 11:38PM  
Dec-10-21 01:36PM  
Dec-09-21 08:16AM  
Dec-08-21 07:38PM  
Dec-07-21 04:35PM  
Dec-06-21 11:32AM  
Nov-30-21 04:05PM  
Nov-22-21 08:00AM  
Nov-09-21 04:01PM  
Nov-02-21 03:14PM  
Nov-01-21 10:00PM  
Oct-26-21 10:36AM  
Oct-25-21 03:01PM  
Oct-18-21 12:31PM  
Oct-16-21 05:00PM  
Oct-13-21 11:30AM  
Oct-11-21 04:01PM  
Oct-08-21 07:29AM  
Sep-20-21 08:52AM  
Sep-10-21 09:23AM  
Sep-08-21 08:30AM  
Sep-02-21 04:13PM  
Aug-05-21 04:01PM  
Aug-03-21 10:31PM  
Jul-27-21 03:03PM  
Jul-22-21 12:10PM  
Jul-19-21 04:01PM  
Jul-08-21 04:01PM  
Jul-06-21 11:49AM  
Jun-21-21 05:53AM  
Jun-01-21 04:01PM  
May-11-21 04:01PM  
May-06-21 06:14AM  
May-05-21 05:15PM  
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lloyd-Smith MalcolmChief Regulatory OfficerAug 15Option Exercise45.968,043369,66326,931Aug 16 06:44 PM
Lloyd-Smith MalcolmChief Regulatory OfficerAug 12Option Exercise35.9921,533774,97340,421Aug 16 06:44 PM
Lloyd-Smith MalcolmChief Regulatory OfficerAug 12Sale105.9521,5332,281,33118,888Aug 16 06:44 PM
Cooke JulieChief Human Resources OfficerJun 27Sale100.0075475,40016,918Jun 29 04:26 PM
POPS RICHARD FDirectorMay 09Option Exercise6.6615,00099,90037,012May 11 05:36 PM
POPS RICHARD FDirectorMay 09Sale76.3015,0001,144,46229,512May 11 05:36 PM
LYONS GARY ADirectorApr 25Option Exercise6.6615,00099,900223,697Apr 27 05:26 PM
LYONS GARY ADirectorApr 25Sale92.7615,0001,391,392208,697Apr 27 05:26 PM
RASTETTER WILLIAM HDirectorApr 01Option Exercise6.6620,000133,20044,750Apr 05 06:20 PM
RASTETTER WILLIAM HDirectorApr 01Sale94.9310,7281,018,36634,022Apr 05 06:20 PM
Lippoldt DarinChief Legal OfficerMar 22Sale95.058,455803,65629,396Mar 22 06:55 PM
Lippoldt DarinChief Legal OfficerMar 18Sale95.0030028,50037,851Mar 22 06:55 PM
ABERNETHY MATTChief Financial OfficerFeb 08Sale79.6598078,05820,204Feb 09 06:51 PM
BENEVICH ERICChief Commercial OfficerFeb 08Sale79.6798078,07320,338Feb 09 06:53 PM
Cooke JulieChief Human Resources OfficerFeb 08Sale79.5670055,68917,411Feb 09 06:55 PM
ROBERTS EIRYChief Medical OfficerFeb 08Sale79.5298077,93124,625Feb 09 07:06 PM
Boyer David W.Chief Corp. Affairs OfficerFeb 08Sale79.6270055,7362,919Feb 09 08:04 PM
Gano KyleChief Business Development OffFeb 08Sale79.6798078,079111,173Feb 09 06:58 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 08Sale79.492,274180,768462,844Feb 09 07:00 PM
Lippoldt DarinChief Legal OfficerFeb 08Sale79.5191172,43538,112Feb 09 07:03 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 08Sale79.5370155,75118,731Feb 09 07:04 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 07Sale80.722,681216,41716,474Feb 09 07:04 PM
Lippoldt DarinChief Legal OfficerFeb 07Sale80.723,168255,72534,993Feb 09 07:03 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 07Sale80.828,710703,907455,150Feb 09 07:00 PM
Gano KyleChief Business Development OffFeb 07Sale80.775,900476,549105,619Feb 09 06:58 PM
Boyer David W.Chief Corp. Affairs OfficerFeb 07Sale81.0724019,4572,291Feb 09 08:04 PM
ROBERTS EIRYChief Medical OfficerFeb 07Sale80.782,744221,66022,741Feb 09 07:06 PM
Cooke JulieChief Human Resources OfficerFeb 07Sale80.652,158174,03815,386Feb 09 06:55 PM
BENEVICH ERICChief Commercial OfficerFeb 07Sale80.784,119332,74816,483Feb 09 06:53 PM
ABERNETHY MATTChief Financial OfficerFeb 07Sale80.793,310267,42818,175Feb 09 06:51 PM
SHERWIN STEPHEN ADirectorJan 24Option Exercise6.6615,00099,90040,055Jan 26 05:52 PM
SHERWIN STEPHEN ADirectorJan 24Sale74.4315,0001,116,37825,055Jan 26 05:52 PM
ROBERTS EIRYChief Medical OfficerJan 10Sale74.502,632196,08821,279Jan 12 05:53 PM
Gano KyleChief Business Development OffJan 05Option Exercise8.6628,266244,784133,250Jan 07 06:04 PM
Gano KyleChief Business Development OffJan 05Sale85.5028,2662,416,751104,984Jan 07 06:04 PM
ABERNETHY MATTChief Financial OfficerDec 01Sale82.591,645135,85216,349Dec 03 05:02 PM
Grigoriadis Dimitri E.Chief Research OfficerOct 07Option Exercise43.245,000216,20087,273Oct 12 06:32 PM
LYONS GARY ADirectorOct 07Sale105.065,000525,294208,697Oct 12 06:34 PM
Grigoriadis Dimitri E.Chief Research OfficerOct 07Sale104.818,000838,51082,273Oct 12 06:32 PM
Cooke JulieChief Human Resources OfficerOct 04Sale101.73987100,40814,841Oct 06 04:37 PM